Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Small Cell Lung Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Stomach Neoplasms|Triple Negative Breast Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Esophagogastric Junction Neoplasms|Carcinoma, Pancreatic Ductal|Esophageal Squamous Cell Carcinoma
Interventions: DRUG: paclitaxel + carboplatin|DRUG: carboplatin + etoposide|DRUG: gemcitabine + carboplatin|DRUG: nab-paclitaxel (paclitaxel-albumin) + carboplatin|DRUG: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|BIOLOGICAL: durvalumab|BIOLOGICAL: tremelimumab|DRUG: nab-paclitaxel (paclitaxel-albumin) + gemcitabine|DRUG: cisplatin + 5-fluorouracil (5FU)
Sponsor: AstraZeneca